AstraZeneca spins out a bispecific antibody into a new cancer biotech with partner AbPro
AstraZeneca’s big subsidiary MedImmune and synthetic biology player AbPro are joining forces on a spin-out company which will undertake the development of a preclinical …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.